JP2024508372A5 - - Google Patents

Info

Publication number
JP2024508372A5
JP2024508372A5 JP2023546027A JP2023546027A JP2024508372A5 JP 2024508372 A5 JP2024508372 A5 JP 2024508372A5 JP 2023546027 A JP2023546027 A JP 2023546027A JP 2023546027 A JP2023546027 A JP 2023546027A JP 2024508372 A5 JP2024508372 A5 JP 2024508372A5
Authority
JP
Japan
Prior art keywords
adhd
compound
compound according
administered
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508372A (ja
Filing date
Publication date
Priority claimed from GBGB2101292.7A external-priority patent/GB202101292D0/en
Priority claimed from GBGB2101291.9A external-priority patent/GB202101291D0/en
Priority claimed from GBGB2101296.8A external-priority patent/GB202101296D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/052142 external-priority patent/WO2022162199A2/en
Publication of JP2024508372A publication Critical patent/JP2024508372A/ja
Publication of JP2024508372A5 publication Critical patent/JP2024508372A5/ja
Pending legal-status Critical Current

Links

JP2023546027A 2021-01-29 2022-01-28 注意欠陥／多動性障害の治療又は予防に使用するための化合物 Pending JP2024508372A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2101292.7A GB202101292D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101291.9A GB202101291D0 (en) 2021-01-29 2021-01-29 Novel treatments
GB2101296.8 2021-01-29
GB2101291.9 2021-01-29
GB2101292.7 2021-01-29
GBGB2101296.8A GB202101296D0 (en) 2021-01-29 2021-01-29 Novel treatments
PCT/EP2022/052142 WO2022162199A2 (en) 2021-01-29 2022-01-28 Novel treatments

Publications (2)

Publication Number Publication Date
JP2024508372A JP2024508372A (ja) 2024-02-27
JP2024508372A5 true JP2024508372A5 (https=) 2025-07-17

Family

ID=80682355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546027A Pending JP2024508372A (ja) 2021-01-29 2022-01-28 注意欠陥／多動性障害の治療又は予防に使用するための化合物

Country Status (12)

Country Link
US (1) US20240130995A1 (https=)
EP (1) EP4284356B1 (https=)
JP (1) JP2024508372A (https=)
AU (1) AU2022215118A1 (https=)
CA (1) CA3206935A1 (https=)
ES (1) ES3038949T3 (https=)
HR (1) HRP20250747T1 (https=)
HU (1) HUE071725T2 (https=)
PL (1) PL4284356T3 (https=)
RS (1) RS66934B1 (https=)
SM (1) SMT202500238T1 (https=)
WO (1) WO2022162199A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093748A1 (en) * 2023-11-03 2025-05-08 3Z Pharmaceuticals Use of a calcium channel blocker in the treatment of adhd

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1030672A1 (en) * 1997-11-19 2000-08-30 Merck & Co., Inc. Method for treating attention deficit disorder
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
CA2546395A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
WO2011100659A2 (en) * 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
PL2895507T3 (pl) * 2012-09-11 2019-04-30 Inst Catalana De Recerca I Estudis Avancats Sposób diagnostyczny do wykrywania choroby autoimmunologicznej oraz przedmioty z nim związane
WO2014133329A1 (ko) * 2013-02-27 2014-09-04 에스케이케미칼 주식회사 관절염 치료용 복합 제제
KR20140135676A (ko) * 2014-10-02 2014-11-26 한국과학기술원 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물
JP2021500416A (ja) * 2017-10-27 2021-01-07 エステベ ファーマスーティカルズ，ソシエダッド アノニマ 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions

Similar Documents

Publication Publication Date Title
RU2317817C2 (ru) Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства
ES2542891T3 (es) Terapia de combinación para el tratamiento de apnea del sueño asociada con la obesidad
US20040122090A1 (en) Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2002045710A9 (en) Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2016065085A (ja) モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
TW200808696A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
JP2024508372A5 (https=)
JP2025504984A5 (https=)
HRP20250747T1 (hr) Spojevi namijenjeni upotrebi u liječenju poremećaja hiperaktivnosti i nedostatka pažnje
JP2023526517A (ja) 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ
US20160022659A1 (en) Methods for treating attention deficit hyperactivity disorder using a combination of bupropion ((±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one) and phentermine (2-methyl-1-phenylpropan-2-amine)
Forcen et al. Ketamine with psychotherapy for the treatment of depression
RU2403922C2 (ru) Способ восстановительного лечения больных артериальной гипертензией с метаболическими нарушениями
JPS63500796A (ja) アミノシクロアルキルアミドの抗不整脈剤用途
CN105012233B (zh) 一种含有普鲁卡因的用于分娩的组合物及制备方法
CN101601665A (zh) 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用
TWI297605B (en) 1-amino-alkylcyclohexanes as trypanocidal agents
WO2022007578A1 (zh) 治疗阿尔茨海默病的组合及其应用
BR112021005193A2 (pt) medicamento e combinação para a prevenção, alívio ou tratamento de transtorno de estresse agudo ou transtorno de estresse pós-traumático, e, medicamento para a prevenção, alívio ou tratamento de sintoma de transtorno de estresse pós-traumático
US8013016B2 (en) Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome
JP6466792B2 (ja) 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
MX2012005661A (es) Tratamiento de exacerbacion aguda de asma y reduccion de probabilidad de hospitalizacion de pacientes que sufren de la misma.
EP4531826A1 (en) Use of 5-methoxy-2-aminoindan ("meai") in methods for treating cocaine addiction
Lorimer et al. Cardiovascular disease
EP1852113A2 (en) Methods for treating neuropsychiatric disorders with NMDA receptors antagonists